P.O. Box 3660, Riyadh 11481, Mail Code 1515 (KAIMRC)
+966 (11) 429-4444
+966 (11) 429-4440

Publication Details

Title :

Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care

Journal:

Blood Rev.

Impact Factor:

6.600

Authors:

Damlaj M1, El Fakih R2, Hashmi SK3.

Affiliations:

1 Division of Hematology & HSCT, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

2 Division of Adult Hematology & Stem Cell Transplantation, Oncology Center, King Faisal Specialist Hospital and Research Center, s, Saudi Arabia.

3 Division of Adult Hematology & Stem Cell Transplantation, Oncology Center, King Faisal Specialist Hospital and Research Center, s, Saudi Arabia; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Address reprint requests to Dr. Arabi at the Intensive Care Department, Ministry of National Guard Health Affairs, ICU 1425, P.O. Box 22490, Riyadh 11426, Saudi Arabia, or at arabi@ngha.med.sa.

Year of Publication:

2019

DOI:

10.1016/j.blre.2018.07.003

Abstract:

Recent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for the practicing clinicians for optimal patient management. In this review, we describe the genesis of the field of cancer survivorship, and then it’s gentle metamorphosis into multiple sub-fields currently by presenting literature relevant to late effects commonly seen in Hodgkin lymphoma, non-Hodgkin lymphoma, chronic leukemia and multiple myeloma. We will discuss the strengths and pitfalls of the existing models of survivorship care in hematologic malignancies and conclude with expert perspective on how to move the field forward.